Problem

Exin Therapeutics is tackling neurological and neuropsychiatric disorders in which disrupted neural-circuit activity produces debilitating symptoms. Its initial use cases include epilepsy associated with autism, autism-spectrum symptoms such as sensory hypersensitivity, and Parkinson’s disease. The company frames these conditions as problems of excitatory/inhibitory imbalance: circuits can be excessively active, as in seizures, or otherwise dysregulated in ways that impair how the brain processes information and responds to the world.

The pain is both clinical and economic. Neurological disorders are difficult to treat, have high failure rates in drug development, and lack reliable biomarkers and patient-focused endpoints. One estimate places the annual U.S. economic burden of major neurological diseases at approximately $800 billion. Exin’s killer use case is therefore to find treatments that can correct disease-relevant circuit activity more precisely, especially where conventional drug-development approaches are slow and expensive.

Product / Service

Exin is building an AI-enabled target-discovery and neurotherapeutics platform rather than selling an approved therapy today. It combines high-throughput in-vivo mouse studies with multimodal data—including neural activity, behavior, and transcriptomics—to train models that identify disease drivers, predict which therapeutic candidates may work across indications, and provide efficacy readouts during preclinical testing. The aim is to prioritize the most promising candidates before spending further time and funding on experiments.

Its therapeutic concept is circuit-level modulation: instead of correcting a missing gene, Exin says it can supplement existing genes whose activity directly changes neural activity in the desired direction, independently of a patient’s genetic background. The platform is designed to be agnostic to therapeutic modality, support multi-target and highly localized effects, and potentially identify one candidate’s relevance across multiple neural disorders.

Market

Exin competes in the emerging market for AI-enabled neurotherapeutics and neuroscience drug discovery, with a distinctive emphasis on neural circuits and genetic-background-agnostic therapies. The competitive set is partly adjacent rather than identical: Verge uses AI and human data for drug discovery, Neurona Therapeutics is developing cell therapies that integrate into neural circuits, and Crunchbase lists Cognito Therapeutics, Neumora Therapeutics, and Alzheon as possible alternatives. These companies illustrate the broader competition for better, more precise treatments for brain disorders, although the available evidence does not establish that all use Exin’s exact modality.

Exin appears to be an early-stage, preclinical and effectively pre-revenue company, with no marketed product, clinical-stage program, or disclosed revenue in the gathered materials. Its disclosed traction is technical: YC described an operating animal lab, proof of concept in mice, a multimodal AI model guiding screening, and two provisional patent filings shortly after launch. A third-party company profile reports a $500,000 seed round in January 2025, while YC lists the company as active and founded in 2024.